Aravive Inc. (ARAV) PT Lowered to $15 at Wedbush, Following Earnings
- Wall Street opens higher as taper fears ease
- China Tells Local Authorities to Prepare For a 'Possible Storm' and Prevent Unrest as Evergrande Crisis Unravels - WSJ
- Salesforce (CRM) Raises FY22 Revenue Guidance; Initiates FY23 Revenue
- Oil prices at two-month highs on tight supplies
- IDFA Seen as a 'Real Headwind' for Facebook (FB) but Analysts Remain Positive
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Wedbush analyst David Nierengarten lowered the price target on Aravive Inc. (NASDAQ: ARAV) to $15.00 (from $24.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Syros Pharmaceuticals (SYRS) PT Raised to $23 at Roth Capital
- Paramount Resources Ltd (POU:CN) (PRMRF) PT Raised to Cdn$22 at Stifel Canada
- Spartan Delta Corp (SDE:CN) (DALXF) PT Raised to Cdn$7.25 at Stifel Canada
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!